Global healthcare company GlaxoSmithKline (GSK) is expanding its operations in Scotland backed by £25 million investment to support the delivery of its new pipeline of medicines.
GSK is investing in new state-of-the-art facilities and equipment in Montrose where it will produce the ingredients for four new pharmaceutical products.
Ours is a fast-moving and competitive environment and the investment should be seen as a vote of confidence in the skills, standards and drive of the people who work here.
Roger Connor, President, Global Manufacturing and Supply for GSK
The investment will create an additional 25 new jobs for process technicians, engineers and chemists – bringing the total GSK workforce in Scotland to more than 750. An additional fifty contractors will be employed during the construction phase.
This investment comes on top of GSK’s pledge in 2012 to invest £100 million in Montrose and the company’s other Scottish manufacturing site in Irvine.
Right skills and experience
In recent years, the company has also invested approximately £40 million in bringing technology and capability to Scotland that was previously undertaken overseas.
Currently, Montrose produces active ingredients for a number of medicines in important disease areas such as respiratory and HIV/AIDS while the Irvine site produces antibiotics. These ingredients and products are exported globally and the sites are an integral part of GSK’s overall manufacturing network.
Finance Secretary John Swinney said: “GSK’s investment is testament to the skill of the Scottish workforce and illustrates the confidence international companies have in Scotland as a country to invest in.
“Montrose has the infrastructure, experience and skills to deliver success for GSK and the company’s commitment to Scotland is further positive news for financial enterprise and the wider Scottish economy.
Roger Connor, President, Global Manufacturing and Supply for GSK, said the announcement is a vote of confidence in the GSK Montrose team:
“Our teams in Montrose and Irvine are world class and have worked hard to bring new facilities to the two sites. This investment shows how highly we value our teams in Scotland.
“Our people here in Montrose manufacture the primary ingredients that then go forward to be put in inhalers, pills, capsules and injections for patients across the globe. Montrose will work alongside our sister site in Singapore to meet international demand for some of the world’s most important medicines.
Angus Council leader, Cllr Iain Gaul said: "The investment from Scottish Enterprise will support our work to improve the roads in the area and further enhance the port’s reputation as a world-class location for business.
Scottish Enterprise provided £1.5 million to Angus Council in support of its “Unlocking South Montrose” Master Plan – a two-phase, £4.2 million road infrastructure project.
To date GSK has received over £20 million of direct financial support.
The company has benefitted from our advice in areas of:
- R&D and process improvement
- Building feasibility study
- Capacity development
- Training and management development
"We believe this project will help attract further inward investment to the area and support the existing companies to take forward investment plans.”
Jim McFarlane, executive director at Scottish Enterprise said:“We have a long-standing account management relationship with GSK. We’ve been involved in some of the key strategic projects that have helped the company reach its current level of success.
“Last year we were involved in discussions about how it might expand further, and it became apparent GSK felt the lack of strong travel and transport infrastructure was an obstacle to future investment on the site.
“We were aware that Angus Council had a plan to address the issue, but didn’t have all the funding in place to implement it. We therefore decided to support the council’s project, allowing it to go ahead almost immediately and, as a result, allowing GSK to continue investing in the Montrose facility."
Support for investors in Scotland